No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
AMPH240517P45000
- 3.30
- +0.35+11.86%
15min DelayClose May 16 15:59 ET
3.30High3.05Low
3.15Open2.95Pre Close7 Volume27 Open Interest45.00Strike Price2.27KTurnover196.06%IV-2.43%PremiumMay 17, 2024Expiry Date2.26Intrinsic Value100Multiplier1DDays to Expiry1.04Time Value100Contract SizeAmericanOptions Type-0.6551Delta0.0764Gamma12.95Leverage Ratio-0.9004Theta-0.0010Rho-8.48Eff Leverage0.0091Vega
Intraday
- 5D
- 1D
News
Amphastar Pharmaceuticals | 10-Q: Quarterly report
Amphastar Pharmaceuticals Reports Strong First Quarter Earnings, Surpassing Analyst Revenue ...
Amphastar Pharmaceuticals to Present at the Bank of America Securities Health Care Conference
RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in
Analysts Offer Insights on Healthcare Companies: Amphastar Pharmaceuticals (AMPH) and Erasca (ERAS)
Earnings Call Summary | Amphastar Pharmaceuticals(AMPH.US) Q1 2024 Earnings Conference
The following is a summary of the Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2024 Earnings Call Transcript:Financial Performance:Amphastar reported a 23% year-over-year increase in net revenue to $171.
Q1 2024 Amphastar Pharmaceuticals Inc Earnings Call
Comments
The market's growth expectations seem moderated as EPS growth outpaces average annual share price increase. The recent rise in total shareholder return could suggest business improvement over time.
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Performs Better Than Its Underlying Earnings Growth Over Last Three YearsThe impressive EPS growth and large insider ownership make Amphastar Pharmaceuticals a potentially attractive investment. The business appears to have reached a growth inflection point.
Insider ownership is moderately high, showing company's interest for all shareholders, but the lack of insider buying and significant selling over the last year, casts some doubt on the company's outlook.
Amphastar Pharmaceuticals experienced a dip, but long-term its performance is strong due to profitability transition and faster EPS growth versus share price. However, market growth expectations are moderated. Share price momentum indicates a potential investment opportunity.
$Amphastar Pharmaceuticals(AMPH.US$ any good news?
Read more